Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Study Finds Critical Genes for Viral Lymphoma
Disease Discoveries

Study Finds Critical Genes for Viral Lymphoma

By Will DossOct 5, 2018
Share
Facebook Twitter Email
The authors of the study show that primary effusion lymphoma cells are addicted to high levels of the anti-apoptotic protein MCL1 (brown stain), which offers an attractive therapeutic target for this disease.

Northwestern Medicine scientists have identified hundreds of key genes in primary effusion lymphoma and highlighted two genes that, when inhibited, may slow progression of the cancer, according to a study published in Nature Communications.

This large, unbiased genetic screen paints a new picture of how the disease works, according to Eva Gottwein, PhD, assistant professor of Microbiology-Immunology and senior author of the study.

“We’ve identified some very critical genes that had not yet been implicated in this cancer,” said Gottwein, who is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Eva Gottwein, PhD, assistant professor of Microbiology-Immunology, member of the Robert H. Lurie Comprehensive Cancer Center and senior author of the study published in Nature Communications.

Primary effusion lymphoma (PEL) is a rare and aggressive cancer caused by the Kaposi’s sarcoma-associated herpesvirus. According to Gottwein, little is known about the oncogenesis of this cancer, making it difficult to identify mechanisms of disease and eventually treatments.

Previous studies of this cancer’s disease mechanisms were often targeted; selecting a candidate gene to study and characterizing how it was involved in the disease. In contrast, the current study was a large-scale unbiased genetic screen in eight unique patient-derived PEL cell lines, searching for any genes that are important to PEL.

Using CRISPR-Cas9 gene editing, the scientists knocked out genes in PEL cells one at a time, creating thousands of variants each with one gene turned off. If a cell didn’t survive, that knocked-out gene was flagged as important. In all, the scientists had identified about 860 genes that were critical to oncogenesis and progression.

In particular, strong dependencies on the proteins expressed by genes Cyclin D2 and MCL1 are a boon for future therapies, as drugs that inhibit those proteins already exist, according to Gottwein.

“It was actually very lucky that the most important genes already have drugs,” Gottwein said. “These cancer cells are specifically addicted to high levels of the encoded proteins, so they’re much more sensitive to these inhibitors than normal cells.”

Cyclin D2 is a gene involved in the cell cycle, and its inhibitor — called palbociclib — is already FDA-approved in breast cancer.

Mark Manzano, PhD, a postdoctoral fellow in the Gottwein laboratory and the first author of the study published in Nature Communications.

“It’s being used in the clinic and specifically targets cyclin-dependent kinases, which are important for the cells to proliferate,” said Mark Manzano, PhD, a postdoctoral fellow in the Gottwein laboratory and the first author of the study.

MCL1’s current patient-approved inhibitors, however, are less specific, targeting not just MCL1 but a variety of genes in the same family. But a newly discovered compound called S63845 could solve that problem by binding only to MCL1, according to Manzano.

“This is a very attractive therapeutic agent, because the last thing we want to do is use drugs that kill other normal cells in the body,” Manzano said.

Next, the investigators plan to test the inhibitors in animal models, working with Northwestern’s Center for Developmental Therapeutics to test the efficacy of the candidate drugs. In addition, they aim to learn more about the cancer itself, informing future therapy.

“For example, the virus encodes for its own form of Cyclin. The importance of that is not understood, but the drugs could potentially also target the viral Cyclin,” Gottwein said. “This is something we could look at in future studies.”

Other Northwestern authors include Ajinkya Patil, research technician in the Gottwein laboratory and Amir Behdad, MD, assistant professor of Pathology and a member of the Robert H. Lurie Comprehensive Cancer Center.

This study was supported by National Cancer Institute grants R21 CA210904 and R01 CA180813, by Searle and Zell Scholar Awards from the Robert H. Lurie Comprehensive Cancer Center and the Chicago Biomedical Consortium Postdoctoral Award PDR-061.

Cancer Genetics Microbiology Research
Share. Facebook Twitter Email

Related Posts

Inflammatory Signaling Linked to Leukemia Progression

Aug 15, 2022

Emerging Therapy for Relapsed Lymphoma

Aug 12, 2022

Scientists Identify Key Mechanism Controlling Skin Regeneration

Aug 11, 2022

Comments are closed.

Latest News

Inflammatory Signaling Linked to Leukemia Progression

Aug 15, 2022

Emerging Therapy for Relapsed Lymphoma

Aug 12, 2022

Scientists Identify Key Mechanism Controlling Skin Regeneration

Aug 11, 2022

Scientists Discover Novel Cellular Mechanisms Behind Transcription Elongation

Aug 10, 2022

First-Year Medical Students Celebrate Founders’ Day 2022

Aug 9, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
egn-flickr
Founders' Day 2022_EGN-retouched
220805_SERIO_MANDELL_FEINBERG_White_Coat_1676
220805_SERIO_MANDELL_FEINBERG_White_Coat_1206
220805_SERIO_MANDELL_FEINBERG_White_Coat_1144 (1)
220805_SERIO_MANDELL_FEINBERG_White_Coat_1133
220805_SERIO_MANDELL_FEINBERG_White_Coat_1057
220805_SERIO_MANDELL_FEINBERG_White_Coat_1424
220805_SERIO_MANDELL_FEINBERG_White_Coat_1472
220805_SERIO_MANDELL_FEINBERG_White_Coat_1573
220805_SERIO_MANDELL_FEINBERG_White_Coat_1671
220805_SERIO_MANDELL_FEINBERG_White_Coat_1793

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.